Results 101 to 110 of about 19,810 (202)

Switching to Tenofovir Therapy Versus Continuation of Entecavir for Patients With Hepatitis B Virus Infection: A Systematic Review and Meta‐Analysis

JGH Open
Background Hepatitis B virus (HBV) infection causes liver disease, including hepatocellular carcinoma. Controlling viral activity is crucial to reducing complications.
Muhammad Shahzil, Ammad Javaid Chaudhary, Talha Kashif, Ali Akram Qureshi, Anza Muhammad, Faiza Khan, Muhammad Saad Faisal, Muhammad Ali Khaqan, Hassam Ali, Yara Dababneh, Dilip Moonka   +10 more
doaj   +1 more source

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

, 2017
Background Tenofovir alafenamide, a tenofovir prodrug, results in 90% lower tenofovir plasma concentrations than does tenofovir disproxil fumarate, thereby minimising bone and renal risks.
Ruane, Peter, SenGupta, Devi, Rijnders, Bart, Adriano Lazzarin, Anders Thalme, Andrew Cheng, Ramgopal, M, Mills, Anthony, Rockstroh, Jürgen, Vandercam, Bernard, Bernard Vandercam, Gordon Crofoot, Marcel Stoeckle, Daniel Podzamczer, de Wet, Joseph, Chloe Orkin, LaMarca, A, Orkin, Chloe, Lazzarin, Adriano, Hui C Liu, Lazzarin, A, Joseph de Wet, Mills, A, Crofoot, G, Liu, Hui C, Rockstroh, J, Danielle Porter, Podzamczer, Daniel, Jürgen Rockstroh, Vandercam, B, Ruane, P, Quirk, Erin, Porter, D, Moti Ramgopal, Edwin DeJesus, Peter Ruane, LaMarca, Anthony, Bart Rijnders, DeJesus, E, Stoeckle, M, DeJesus, Edwin, Cheng, Andrew, Porter, Danielle, Orkin, C, Huyen Cao, de Wet, J, Cao, H, Erin Quirk, Rijnders, Bart; id_orcid, Anthony Mills, Liu, HC, Anthony LaMarca, Thalme, Anders, Ramgopal, Moti, Quirk, E, Podzamczer, D, Thalme, A, Cao, Huyen, Devi SenGupta, Cheng, A, Crofoot, Gordon, Stoeckle, Marcel, SenGupta, D, Podzamczer D, Mills A, DeJesus E, Liu HC, Rijnders B, Crofoot G, Quirk E, Vandercam B, Cao H, SenGupta D, Rockstroh J, Lazzarin A, de Wet J, LaMarca A, Ramgopal M, Cheng A, Stoeckle M, Thalme A, Ruane P, Orkin C, Porter D   +83 more
core   +1 more source

Are patients starting first-line ART with a 2-drug regimen (2DR) with dolutegravir/lamivudine different from those initiating 3-drug regimens (3DR) based on an integrase strand transfer inhibitor (InSTI), plus tenofovir alafenamide/emtricitabine?

, 2021
Background: Aim: To identify patients’ profiles associated with the initiation of a 2DR vs.
G. Madeddu, Icona Foundation Study, G. F. PELLICANO, L. Taramasso, A. Saracino, R. Gagliardini, A. Tavelli, G. Lapadula, A. Cozzi-Lepri, N. Gianotti, A. Antinori, F. Maggiolo, A. d’Arminio Monforte, S. Bonora   +13 more
core  

The Cost-Effectiveness of Tenofovir Alafenamide for Chronic Hepatitis B Virus in Taiwan

MDM Policy & Practice
Background. Chronic hepatitis B (CHB) is a lifelong disease requiring long-term or indefinite therapy, resulting in substantial economic burden. Thus, careful consideration must be used in the selection of therapies. Aim.
Elise Chia-Hui Tan, Alon Yehoshua, Sushanth Jeyakumar, Pongo Peng, Amy Lin, Nathaniel J. Smith, Nandita Kachru   +6 more
doaj   +1 more source

Metabolic Outcomes of Changing From Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine to Rilpivirine/Tenofovir Alafenamide/Emtricitabine: A Longitudinal Study

Health Science Reports
Background and Aims People living with human immunodeficiency virus (HIV, PLWH) are aging, and there are growing concerns regarding combined antiretroviral therapy (cART)‐associated negative metabolic consequences.
Ping‐Feng Wu, Hsi‐Hsun Lin, Hsin‐Pai Chen, Po‐Chieh Huang, Meng‐Yu Ke   +4 more
doaj   +1 more source

Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin. [PDF]

Clin Infect Dis
Osuala EC, Nkuhairwe IN, Letsoalo MP, Naidoo K, Perumal R, Rooney JF, Wiesner L, Wasmann RE, Denti P, Dooley KE, Naidoo A, INSIGHT Study Team.   +11 more
europepmc   +1 more source

A real-world pharmacovigilance study of FDA adverse event reporting system events for bictegravir/emtricitabine/tenofovir alafenamide. [PDF]

Front Pharmacol
Liu Y, Zhang L, Li X, Zhao H.
europepmc   +1 more source

Bictegravir/Tenofovir Alafenamide/Emtricitabine in Real-Life: A Multi-Year Experience. [PDF]

J Clin Med
Gidari A, Baranello E, Pallotto C, Morosi S, Papalini C, Gamboni G, Malincarne L, Rosignoli D, Benvenuto MC, Gonnelli G, Ucciferri C, Socio GV.   +11 more
europepmc   +1 more source

Impact of Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide or Entecavir in Older Patients with Chronic Hepatitis B. [PDF]

Infect Dis Ther
Cesanelli F, Nozza O, Gottardi F, Mosti F, Zaltron S, Tiecco G, Scarvaglieri I, Spinetti A, Castelli F, Quiros-Roldan E.   +9 more
europepmc   +1 more source

Tenofovir Alafenamide for HIV Preexposure Prophylaxis

Annals of Internal Medicine, 2020
Douglas S. Krakower, Demetre C. Daskalakis, Judith Feinberg, Julia L. Marcus   +3 more
openaire   +5 more sources